Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $71.01 USD
Change Today 0.00 / 0.00%
Volume 0.0
MPSYF On Other Exchanges
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MPSYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - $107.45
52 Week Low
03/26/15 - $57.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MORPHOSYS AG (MPSYF)

Related News

No related news articles were found.

morphosys ag (MPSYF) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MPSYF) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of musculoskeletal diseases, Alzheimer‘s disease, and rheumatoid arthritis. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies in the area of inflammatory diseases and oncology. The company’s proprietary product candidates include MOR103, an antibody that is in phase Ib trial for multiple sclerosis; MOR202, a therapeutic antibody that is in phase I/II trial for the treatment of multiple myeloma; and MOR208, which is in phase II clinical trials for patients suffering from diffuse large B-cell lymphoma. MorphoSys AG has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; Celgene Corporation for the co-development of the cancer program MOR202; and immatics biotechnologies GmbH to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. The company was founded in 1992 and is headquartered in Martinsried, Germany.

371 Employees
Last Reported Date: 07/27/15
Founded in 1992

morphosys ag (MPSYF) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag (MPSYF) Key Developments

Morphosys AG and immatics biotechnologies GmbH Enter Strategic Alliance in Immuno-Oncology

Morphosys AG and immatics biotechnologies GmbH announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. The collaboration agreement provides MorphoSys with access to several proprietary tumor-associated peptides (TUMAPs) discovered using Immatics' XPRESIDENT® platform to develop novel antibody-based therapeutics against these targets in a number of solid and hematological cancers. XPRESIDENT® enables access to novel antibody targets associated with proteins that are present inside cancer cells. In return, Immatics will be provided with MorphoSys' Ylanthia® antibodies against a number of its TUMAPs, with proprietary development rights. The companies will pay each other milestones based on their respective development progress as well as royalties on marketed products. Financial details of the agreement were not disclosed.

MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics

MorphoSys AG and G7 Therapeutics AG announced that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sublicense to third parties the access to these targets in conjunction with therapeutic antibody candidates.

Morphosys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Year 2015

Morphosys AG reported earnings results for the second quarter and six months ended June 30, 2015. Net loss for the second quarter 2015 was EUR 4.3 million, compared to a net loss of EUR 0.5 million in the second quarter of 2014. In the second quarter of 2015, the company generated revenues in the amount of EUR 12.2 million, compared to EUR 14.7 million in the same quarter of 2014. LBIT amounted to EUR 6.7 million against 1.0 million a year ago. For the six months, group revenues were EUR 82.6 million against EUR 30.5 million a year ago. The increase is attributable to revenue booked in connection with the ending of the collaboration with Celgene on MorphoSys's proprietary drug candidate MOR202. EBIT amounted to EUR 46.1 million against EUR 0.4 million a year ago. Diluted earnings per share amounted to EUR 1.39 against EUR 0.02 a year ago. The company has reaffirmed its earnings guidance for the year 2015. Group revenues of EUR 101 million to EUR 106 million and anticipates a positive EBIT in the range of EUR 9 to EUR 16 million in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MPSYF:US $71.01 USD 0.00

MPSYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.60 EUR +0.075
Genmab A/S kr597.50 DKK +6.00
ImmunoGen Inc $13.46 USD -0.82
Intrexon Corp $44.50 USD -2.25
XOMA Corp $0.83 USD -0.033
View Industry Companies

Industry Analysis


Industry Average

Valuation MPSYF Industry Range
Price/Earnings 50.3x
Price/Sales 14.2x
Price/Book 4.3x
Price/Cash Flow 50.8x
TEV/Sales 11.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at